Financial Statement, 1 January – 31 December 2011
Operating profit of SEK 111.9 m Huddinge, Sweden—Today, Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its Interim Report for the period 1 January – 31 December and its operational report for the fourth quarter of 2011. Summary of the financial year (January – December) · Net sales were SEK 698.6 (54.9) m · Profit/loss after tax amounted to SEK 113.8 (-134.2) m · Basic and diluted earnings per share were SEK 3.80 (-5.43) · Cash flow from operating activities amounted to SEK 57.3 (-76.9) m; cash and